Asmaa E Kassab1, Ehab M Gedawy1,2, Mohammed I A Hamed3, Ahmed S Doghish4,5, Rasha A Hassan1. 1. Faculty of Pharmacy, Department of Pharmaceutical Organic Chemistry, Cairo University, Cairo, Egypt. 2. Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Badr University in Cairo (BUC), Badr City, Egypt. 3. Faculty of Pharmacy, Department of Organic and Medicinal Chemistry, Fayoum University, Fayoum, Egypt. 4. Faculty of Pharmacy (Boys), Department of Biochemistry, Al-Azhar University, Nasr City, Cairo, Egypt. 5. Faculty of Pharmacy, Department of Biochemistry, Badr University in Cairo (BUC), Badr City, Egypt.
Abstract
Novel tolmetin derivatives 5a-f to 8a-c were designed, synthesised, and evaluated for antiproliferative activity by NCI (USA) against a panel of 60 tumour cell lines. The cytotoxic activity of the most active tolmetin derivatives 5b and 5c was examined against HL-60, HCT-15, and UO-31 tumour cell lines. Compound 5b was found to be the most potent derivative against HL-60, HCT-15, and UO-31 cell lines with IC50 values of 10.32 ± 0.55, 6.62 ± 0.35, and 7.69 ± 0.41 µM, respectively. Molecular modelling studies of derivative 5b towards the VEGFR-2 active site were performed. Compound 5b displayed high inhibitory activity against VEGFR-2 (IC50 = 0.20 µM). It extremely reduced the HUVECs migration potential exhibiting deeply reduced wound healing patterns after 72 h. It induced apoptosis in HCT-15 cells (52.72-fold). This evidence was supported by an increase in the level of apoptotic caspases-3, -8, and -9 by 7.808-, 1.867-, and 7.622-fold, respectively. Compound 5b arrested the cell cycle in the G0/G1 phase. Furthermore, the ADME studies showed that compound 5b possessed promising pharmacokinetic properties.
Novel n class="Chemical">tolmetin derivatives 5a-f to 8a-c were designed, synthesised, and evaluated for antiproliferative activity by NCI (USA) against a panel of 60 tumour cell lines. The cytotoxic activity of the most active tolmetin derivatives 5b and 5c was examined against HL-60, HCT-15, and UO-31tumour cell lines. Compound 5b was found to be the most potent derivative against HL-60, HCT-15, and UO-31 cell lines with IC50 values of 10.32 ± 0.55, 6.62 ± 0.35, and 7.69 ± 0.41 µM, respectively. Molecular modelling studies of derivative 5b towards the VEGFR-2 active site were performed. Compound 5b displayed high inhibitory activity against VEGFR-2 (IC50 = 0.20 µM). It extremely reduced the HUVECs migration potential exhibiting deeply reduced wound healing patterns after 72 h. It induced apoptosis in HCT-15 cells (52.72-fold). This evidence was supported by an increase in the level of apoptotic caspases-3, -8, and -9 by 7.808-, 1.867-, and 7.622-fold, respectively. Compound 5b arrested the cell cycle in the G0/G1 phase. Furthermore, the ADME studies showed that compound 5b possessed promising pharmacokinetic properties.
Authors: Mohamed Hagras; Marwa A Saleh; Rogy R Ezz Eldin; Abdelrahman A Abuelkhir; Emad Gamil Khidr; Ahmed A El-Husseiny; Hesham A El-Mahdy; Eslam B Elkaeed; Ibrahim H Eissa Journal: J Enzyme Inhib Med Chem Date: 2022-12 Impact factor: 5.051
Authors: Reda G Yousef; Wagdy M Eldehna; Alaa Elwan; Abdelaziz S Abdelaziz; Ahmed B M Mehany; Ibraheem M M Gobaara; Bshra A Alsfouk; Eslam B Elkaeed; Ahmed M Metwaly; Ibrahim H Eissa Journal: Molecules Date: 2022-06-24 Impact factor: 4.927
Authors: Hazem Elkady; Alaa Elwan; Hesham A El-Mahdy; Ahmed S Doghish; Ahmed Ismail; Mohammed S Taghour; Eslam B Elkaeed; Ibrahim H Eissa; Mohammed A Dahab; Hazem A Mahdy; Mohamed M Khalifa Journal: J Enzyme Inhib Med Chem Date: 2022-12 Impact factor: 5.051
Authors: Peter A Halim; Rasha A Hassan; Khaled O Mohamed; Soha O Hassanin; Mona G Khalil; Amr M Abdou; Eman O Osman Journal: J Enzyme Inhib Med Chem Date: 2022-12 Impact factor: 5.051
Authors: Salem S Salem; Amr H Hashem; Al-Aliaa M Sallam; Ahmed S Doghish; Abdulaziz A Al-Askar; Amr A Arishi; Amr M Shehabeldine Journal: Polymers (Basel) Date: 2022-08-17 Impact factor: 4.967